PARP1 and small cell lung carcinoma: Gay et al. report that SCLC-P cell lines are sensitive to cisplatin, to PARP-inhibitors (PARPis), and to antimetabolites (anti-folates), whereas SCLC-N and especially SCLC-I cell lines are refractory to cisplatin.